Advertisement

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer

  • Howard H. Bailey
  • Steven Attia
  • Richard R. Love
  • Terri Fass
  • Rick Chappell
  • Kendra Tutsch
  • Linda Harris
  • Alcee Jumonville
  • Richard Hansen
  • Gary R. Shapiro
  • James A. Stewart
Original Article

Abstract

Purpose

Perillyl alcohol (POH) is a naturally occurring lipid with preclinical activity against mammary carcinomas. We conducted a phase II multi-institutional study of oral POH administered four times daily in women with advanced treatment-refractory breast cancer.

Methods

Eligible women were treated with POH four times daily at 1,200–1,500 mg m−2 dose−1 on a 28-day cycle. Patients tolerating 1,200 mg m−2 day−1 four times daily after one cycle were dose-escalated to 1,500 mg/m2. The primary endpoint was 1-year freedom-from-progression (FFP) rate. Secondary endpoints were response rate, tolerability and correlative evaluations.

Results

Twenty-nine cycles of POH were administered to 14 women. Three patients were dose-escalated to 1,500 mg/m2. Grade 1 and grade 2 gastrointestinal effects and fatigue were predominant toxicities. Of seven patients receiving up to one cycle, three stopped therapy due to intolerance. Only two patients received more than two cycles, with disease stabilization of 3 and 8 months. Thirteen patients were evaluable for response. One-year FFP rate was zero. No objective responses were seen. The median time to progression was 35 days (95% CI, 29–123 days). Median overall survival was 389 days (95% CI, 202–776 days). Pharmacokinetic parameters were similar to previous investigations. The ability to correlate plasma TGF-β1 levels with outcome was limited by lack of clinical benefit and inter- and intra-patient variability.

Conclusions

Enrollment was suspended short of planned accrual because of lack of response and poor tolerance to POH. This regimen does not appear to provide benefit in advanced treatment-refractory breast carcinoma.

Keywords

Breast cancer Monoterpenes Perillyl alcohol Phase II 

Notes

Acknowledgments

We thank our patients and their families for their contribution to the advancement of clinical breast cancer research. We thank Marcia Pomplun and Amy Dresen of the University of Wisconsin Carbone Cancer Center 3P Laboratory for their technical assistance with the perillyl alcohol and TGF-β1 assays. We are grateful to Bo Huang for his statistical assistance as well as to Amyé Tevaarwerk for proofreading the manuscript. This study was supported by National Institutes of Health grants R21 CA 72500 and P30 CA 14520 as well as NCRR grant MOI RR03186.

References

  1. 1.
    Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA et al (1995) Paclitaxel activity in heavily pretreated breast cancer: a national cancer institute treatment referral center trial. J Clin Oncol 13:2056–2065PubMedGoogle Scholar
  2. 2.
    Ariazi EA, Satomi Y, Ellis MJ, Haag JD, Shi W, Sattler CA, Gould MN (1999) Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59:1917–1928PubMedGoogle Scholar
  3. 3.
    Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel ER, Kris MG (2003) A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 51:493–498PubMedGoogle Scholar
  4. 4.
    Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S (2002) A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: eastern cooperative oncology group study E2E96. Gynecol Oncol 85:464–468PubMedCrossRefGoogle Scholar
  5. 5.
    Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ (2004) A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol 54:368–376PubMedCrossRefGoogle Scholar
  6. 6.
    Bardon S, Foussard V, Fournel S, Loubat A (2002) Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. Cancer Lett 181:187–194PubMedCrossRefGoogle Scholar
  7. 7.
    Bardon S, Picard K, Martel P (1998) Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 32:1–7PubMedCrossRefGoogle Scholar
  8. 8.
    Berchtold CM, Chen KS, Miyamoto S, Gould MN (2005) Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. Cancer Res 65:8558–8566PubMedCrossRefGoogle Scholar
  9. 9.
    Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–93PubMedGoogle Scholar
  10. 10.
    Broitman SA, Wilkinson Jt, Cerda S, Branch SK (1996) Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic “metastases” in vivo. Adv Exp Med Biol 401:111–130PubMedGoogle Scholar
  11. 11.
    Burke YD, Stark MJ, Roach SL, Sen SE, Crowell PL (1997) Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 32:151–156PubMedCrossRefGoogle Scholar
  12. 12.
    Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731–2736PubMedGoogle Scholar
  13. 13.
    Chan NL, Wang H, Wang Y, Leung HY, Leung LK (2006) Polycyclic aromatic hydrocarbon-induced CYP1B1 activity is suppressed by perillyl alcohol in MCF-7 cells. Toxicol Appl Pharmacol 213:98–104PubMedCrossRefGoogle Scholar
  14. 14.
    Chung BH, Lee HY, Lee JS, Young CY (2006) Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 236:222–228PubMedCrossRefGoogle Scholar
  15. 15.
    Clark SS (2006) Perillyl alcohol induces c-Myc-dependent apoptosis in Bcr/Abl-transformed leukemia cells. Oncology 70:13–18PubMedCrossRefGoogle Scholar
  16. 16.
    Clark SS, Perman SM, Sahin MB, Jenkins GJ, Elegbede JA (2002) Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 16:213–222PubMedCrossRefGoogle Scholar
  17. 17.
    Clark SS, Zhong L, Filiault D, Perman S, Ren Z, Gould M, Yang X (2003) Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion. Clin Cancer Res 9:4494–4504PubMedGoogle Scholar
  18. 18.
    Crowell PL, Chang RR, Ren ZB, Elson CE, Gould MN (1991) Selective inhibition of isoprenylation of 21–26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266:17679–17685PubMedGoogle Scholar
  19. 19.
    Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C (1996) Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel—a phase II study. Cancer Chemother Pharmacol 39:150–156PubMedCrossRefGoogle Scholar
  20. 20.
    Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York, pp 445–449Google Scholar
  21. 21.
    Gomez-Contreras PC, Hernandez-Flores G, Ortiz-Lazareno PC, Del Toro-Arreola S, Delgado-Rizo V, Lerma-Diaz JM, Barba-Barajas M, Dominguez-Rodriguez JR, Bravo Cuellar A (2006) In vitro induction of apoptosis in U937 cells by perillyl alcohol with sensitization by pentoxifylline: increased BCL-2 and BAX protein expression. Chemotherapy 52:308–315PubMedCrossRefGoogle Scholar
  22. 22.
    Gregory WM, Smith P, Richards MA, Twelves CJ, Knight RK, Rubens RD (1993) Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 68:988–995PubMedGoogle Scholar
  23. 23.
    Haag JD, Gould MN (1994) Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34:477–483PubMedCrossRefGoogle Scholar
  24. 24.
    Haag JD, Lindstrom MJ, Gould MN (1992) Limonene-induced regression of mammary carcinomas. Cancer Res 52:4021–4026PubMedGoogle Scholar
  25. 25.
    He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE (1997) Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 127:668–674PubMedGoogle Scholar
  26. 26.
    Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM (2000) Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6:3071–3080PubMedGoogle Scholar
  27. 27.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRefGoogle Scholar
  28. 28.
    Jirtle RL, Haag JD, Ariazi EA, Gould MN (1993) Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 53:3849–3852PubMedGoogle Scholar
  29. 29.
    Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  30. 30.
    Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G (2003) Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 21:367–372PubMedCrossRefGoogle Scholar
  31. 31.
    Loutrari H, Hatziapostolou M, Skouridou V, Papadimitriou E, Roussos C, Kolisis FN, Papapetropoulos A (2004) Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp Ther 311:568–575PubMedCrossRefGoogle Scholar
  32. 32.
    Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP (2002) Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer 32:125–128PubMedCrossRefGoogle Scholar
  33. 33.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRefGoogle Scholar
  34. 34.
    NCI Common Toxicity Criteria version 1.0. http://www.fda.gov/cder/cancer/toxicityframe.htm, accessed 14 May 2007
  35. 35.
    Phillips LR, Malspeis L, Supko JG (1995) Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog. Drug Metab Dispos 23:676–680PubMedGoogle Scholar
  36. 36.
    Qi C, Park JH, Gibbs TC, Shirley DW, Bradshaw CD, Ella KM, Meier KE (1998) Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J Cell Physiol 174:261–272PubMedCrossRefGoogle Scholar
  37. 37.
    Rajesh D, Howard SP (2003) Perillyl alcohol mediated radiosensitization via augmentation of the Fas pathway in prostate cancer cells. Prostate 57:14–23PubMedCrossRefGoogle Scholar
  38. 38.
    Rajesh D, Stenzel RA, Howard SP (2003) Perillyl alcohol as a radio-/chemosensitizer in malignant glioma. J Biol Chem 278:35968–35978PubMedCrossRefGoogle Scholar
  39. 39.
    Reddy BS, Wang CX, Samaha H, Lubet R, Steele VE, Kelloff GJ, Rao CV (1997) Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 57:420–425PubMedGoogle Scholar
  40. 40.
    Ren Z, Gould MN (1998) Modulation of small G protein isoprenylation by anticancer monoterpenes in in situ mammary gland epithelial cells. Carcinogenesis 19:827–832PubMedCrossRefGoogle Scholar
  41. 41.
    Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH (2000) Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 6:390–396PubMedGoogle Scholar
  42. 42.
    Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH (1998) Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4:1159–1164PubMedGoogle Scholar
  43. 43.
    Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero Acuna L et al (1994) Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336–341PubMedGoogle Scholar
  44. 44.
    Sahin MB, Perman SM, Jenkins G, Clark SS (1999) Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines. Leukemia 13:1581–1591PubMedCrossRefGoogle Scholar
  45. 45.
    Samaila D, Toy BJ, Wang RC, Elegbede JA (2004) Monoterpenes enhanced the sensitivity of head and neck cancer cells to radiation treatment in vitro. Anticancer Res 24:3089–3095PubMedGoogle Scholar
  46. 46.
    Shi W, Gould MN (2002) Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol. Carcinogenesis 23:131–142PubMedCrossRefGoogle Scholar
  47. 47.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  48. 48.
    Stark MJ, Burke YD, McKinzie JH, Ayoubi AS, Crowell PL (1995) Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 96:15–21PubMedCrossRefGoogle Scholar
  49. 49.
    Stayrook KR, McKinzie JH, Burke YD, Burke YA, Crowell PL (1997) Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 18:1655–1658PubMedCrossRefGoogle Scholar
  50. 50.
    Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ (2004) A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 10:7583–7591PubMedCrossRefGoogle Scholar
  51. 51.
    Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886–2894PubMedGoogle Scholar
  52. 52.
    Wagner JE, Huff JL, Rust WL, Kingsley K, Plopper GE (2002) Perillyl alcohol inhibits breast cell migration without affecting cell adhesion. J Biomed Biotechnol 2:136–140PubMedCrossRefGoogle Scholar
  53. 53.
    Wiseman DA, Werner SR, Crowell PL (2007) Cell cycle arrest by the isoprenoids perillyl alcohol, geraniol, and farnesol is mediated by p21(Cip1) and p27(Kip1) in human pancreatic adenocarcinoma cells. J Pharmacol Exp Ther 320:1163–1170PubMedCrossRefGoogle Scholar
  54. 54.
    Xu M, Floyd HS, Greth SM, Chang WC, Lohman K, Stoyanova R, Kucera GL, Kute TE, Willingham MC, Miller MS (2004) Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects. Toxicol Appl Pharmacol 195:232–246PubMedCrossRefGoogle Scholar
  55. 55.
    Yuri T, Danbara N, Tsujita-Kyutoku M, Kiyozuka Y, Senzaki H, Shikata N, Kanzaki H, Tsubura A (2004) Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 84:251–260PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Howard H. Bailey
    • 1
  • Steven Attia
    • 1
  • Richard R. Love
    • 1
  • Terri Fass
    • 1
  • Rick Chappell
    • 1
  • Kendra Tutsch
    • 1
  • Linda Harris
    • 1
  • Alcee Jumonville
    • 2
  • Richard Hansen
    • 3
  • Gary R. Shapiro
    • 4
  • James A. Stewart
    • 1
  1. 1.University of Wisconsin Paul P. Carbone Comprehensive Cancer CenterMadisonUSA
  2. 2.Gundersen HealthCareLaCrosseUSA
  3. 3.Waukesha Regional Cancer CenterWaukeshaUSA
  4. 4.Aurora Sinai Medical CenterMilwaukeeUSA

Personalised recommendations